Acceleration of small intestine contrast study by ceruletide

Abstract

The effect of ceruletide on the small bowel transit time of barium sulfate suspension was studied in 165 patients. The control group consisted of 115 cases. An intramuscular injection of 500--750 ng/kg body weight ceruletide was given in 106 cases (group A), 20 ng/kg ceruletide was intravenously injected in 35 patients (group B), and 40 ng/kg was intravenously injected in 24 cases (group C). The mean transit time in group A was 62 +/- 41 min (mean +/- SD), and 126 +/- 62 min in the corresponding control group of 83 cases. (P less than 0.001). The mean transit time in group B was 65 +/- 50 min, and 69 +/- 56 min in group C, whereas in the corresponding control group of 32 cases the mean transit time was 137 +/- 79 min (P less than 0.01). A normal radiographic pattern was found in 75%, and slightly increased segmental contractions in 21%. Overtonicity and pronounced segmental contractions were seen in 4%. The recommended standardized small bowel study using ceruletide reduces the examination time by roughly one-half and produces simultaneous and uniform opacification of the jejunum and ileum.

Evaluation of intramuscular ceruletide for shortening small bowel transit time

“…If the average time required for a small bowel examination could be decreased to 30-60 minutes by a simple, Address reprint requests' to: relatively noninvasive method, both patients and radiologists would benefit. Previous attempts to accelerate the passage of barium through the small bowel have included manipulations of the barium suspension [5] or of the way the barium is administered [6][7][8][9][10][11][12], and the use of pharmacologic agents [13 28].Previous studies have shown that ceruletide, administered either by intravenous or intramuscular injection, stimulates peristalsis in the distal duodenum, jejunum, and ileum [26][27][28]. Ceruletide is a decapeptide originally isolated from skin extracts of the frog [27].…”

“…The agent is basically the decapeptide from a much larger molecule, cholecystokinin. The drug has been used in more than 1,200 patients and subjects [26]. The adverse effects have been described to be essentially dose-related extensions of pharmacological activity, and for the most part accompany rapid intravenous administration [26].…”

“…The drug has been used in more than 1,200 patients and subjects [26]. The adverse effects have been described to be essentially dose-related extensions of pharmacological activity, and for the most part accompany rapid intravenous administration [26]. With intramuscular administration of doses of 0.5 gg/kg or less, the systemic adverse effects have been described as minimal [26][27][28].…”

“…The adverse effects have been described to be essentially dose-related extensions of pharmacological activity, and for the most part accompany rapid intravenous administration [26]. With intramuscular administration of doses of 0.5 gg/kg or less, the systemic adverse effects have been described as minimal [26][27][28]. The present study was designed to evaluate the efficacy of intramuscular injection of ceruletide for decreasing small bowel transit time in normal volunteers utilizing a double-blind crossover design.…”

“…Previous studies have shown that ceruletide, administered either by intravenous or intramuscular injection, stimulates peristalsis in the distal duodenum, jejunum, and ileum [26][27][28]. Ceruletide is a decapeptide originally isolated from skin extracts of the frog [27].…”